Free Trial
NASDAQ:ACTU

Actuate Therapeutics 7/23/2024 Earnings Report

Actuate Therapeutics logo
$7.18 +0.11 (+1.56%)
As of 03:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Actuate Therapeutics EPS Results

Actual EPS
-$5.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Actuate Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Actuate Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Actuate Therapeutics Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Actuate Therapeutics, Inc.
See More Actuate Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Actuate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Actuate Therapeutics and other key companies, straight to your email.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ:ACTU), a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

View Actuate Therapeutics Profile

More Earnings Resources from MarketBeat